Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Iris Pharma, a France-based ophthalmic contract research organization, has completed its merger with Clirophtha. The combined company will operate under the Iris Pharma name.
Subscribe to our email newsletter
Clirophtha is a contract research organization in Europe and North America that is dedicated to ophthalmology clinical trials.
Iris Pharma said that this merger establishes the first global drug-development services provider to be totally dedicated to ophthalmology, offering a complete range of services to biotechnology and pharmaceutical companies worldwide.
Thierry Caillaud, business development director of Iris Pharma, said: “The cumulative expertise and experience from both companies guarantees that the new Iris Pharma company has excellent know-how and knowledge of each step of drug development, from preformulation and in vivo research to Phase IV and medico-marketing surveys, as well as a global overview of the whole process.”